|By Marketwired .||
|June 16, 2014 08:00 AM EDT||
LYON, FRANCE -- (Marketwired) -- 06/16/14 -- Flamel Technologies (NASDAQ: FLML) today announced today that it has received a Prescription Drug User Fee Act (PDUFA) date of August 6, 2014 from the U.S. Food and Drug Administration (FDA) for its second New Drug Application (NDA). This is Flamel's second NDA for an Unapproved Marketed Drug (UMD). The Company had received a Complete Response Letter (CRL) to its NDA on its April 28, 2014. Flamel resubmitted the NDA on June 6, 2014 and FDA classified the CRL resubmission as a Class 1 response.
About Flamel Technologies. Flamel Technologies SA's (NASDAQ: FLML) business model is to blend high-value internally developed products with its leading drug delivery capabilities. The company markets Bloxiverz (neostigmine methylsulfate) in the USA and manufactures Micropump-based microparticles under FDA-audited GMP guidelines for Coreg CR® (carvedilol phosphate), marketed in the USA by GlaxoSmithKline. The Company has a proprietary pipeline of niche specialty pharmaceutical products, while its drug delivery platforms are focused on the goal of developing safer, more efficacious formulations of drugs to address unmet medical needs. Its pipeline includes biological and chemical drugs formulated with its Medusa and Micropump® (and its applications to the development of liquid formulations, i.e. LiquiTime® and of abuse-deterrent formulations Trigger Lock) proprietary drug delivery platforms. Several Medusa-based products have been successfully tested in clinical trials. The Company is headquartered in Lyon, France and has operations in St. Louis, Missouri, USA, and manufacturing facilities in Pessac, France. Additional information may be found at www.flamel.com.
This release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including certain plans, expectations, goals and projections regarding financial results, product developments and technology platforms. All statements that are not clearly historical in nature are forward-looking, and the words "anticipate," "assume," "believe," "expect," "estimate," "plan," "will," "may," and similar expressions are generally intended to identify forward-looking statements. All forward-looking statements involve risks, uncertainties and contingencies, many of which are beyond our control that could cause actual results to differ materially from those contemplated in such forward-looking statements. These risks include risks that the launch of Bloxiverz will not be as successful as anticipated; our ability to bring other R&D projects of the former Éclat Pharmaceuticals to market may be unsuccessful; FDA may not take action on the status of unapproved versions of neostigmine still on the market; clinical trial results may not be positive or our partners may decide not to move forward; products in the development stage may not achieve scientific objectives or milestones or meet stringent regulatory requirements; products in development may not achieve market acceptance; competitive products and pricing may hinder our commercial opportunities; we may not be successful in identifying and pursuing opportunities to develop our own product portfolio using Flamel's technology; and the risks associated with our reliance on outside parties and key strategic alliances. These and other risks are described more fully in Flamel's Annual Report on Form 20-F for the year ended December 31, 2012 that has been filed with the Securities and Exchange Commission (SEC). All forward-looking statements included in this release are based on information available at the time of the release. We undertake no obligation to update or alter our forward-looking statements as a result of new information, future events or otherwise.
Aug. 29, 2016 03:00 AM EDT Reads: 2,401
Aug. 29, 2016 02:15 AM EDT Reads: 1,820
Aug. 29, 2016 02:15 AM EDT Reads: 2,205
Aug. 29, 2016 01:45 AM EDT Reads: 2,174
Aug. 29, 2016 01:15 AM EDT Reads: 3,012
Aug. 29, 2016 01:00 AM EDT Reads: 2,230
Aug. 29, 2016 12:00 AM EDT Reads: 1,894
Aug. 28, 2016 11:15 PM EDT Reads: 2,153
Aug. 28, 2016 10:30 PM EDT Reads: 4,061
Aug. 28, 2016 08:30 PM EDT Reads: 1,845
Aug. 28, 2016 08:15 PM EDT Reads: 1,957
Aug. 28, 2016 07:30 PM EDT Reads: 717
Aug. 28, 2016 06:30 PM EDT Reads: 1,638
Aug. 28, 2016 06:00 PM EDT Reads: 1,949
Aug. 28, 2016 05:30 PM EDT Reads: 798